Dad's mental health in the first two years has a lasting impact on kids, new study shows
For many mothers, these findings validate something they've long sensed: a partner's emotional state can shape the energy of the entire household. When one parent is silently struggling, it can shift the emotional rhythm of the entire household—including the littlest members of the family.
Researchers found that paternal distress—including anxiety, depression, and chronic stress—was strongly associated with outcomes like emotional dysregulation, cognitive delays, and social difficulties in children. These patterns held true across infancy, toddlerhood, and the preschool years.
The takeaway? Prioritizing dad's mental health isn't just good for him—it's good for kids, too.
Related: This viral TikTok captures what it's like to parent through exhaustion and mental health struggles
Mental health struggles don't always look the same in men as they do in women, especially in the postpartum period. But experts identify several subtle yet telling symptoms, particularly among fathers, that can help partners recognize when to reach out:
Emotional withdrawal or irritability: Some men express depression or anxiety as anger or emotional distance.
Loss of interest in activities they once enjoyed: A sudden disinterest in hobbies, social outings, or time with the kids can be a red flag .
Trouble sleeping or persistent fatigue not tied to parenting: Disrupted sleep patterns—either insomnia or excessive sleeping—along with chronic tiredness are common symptoms in dads .
Avoiding time with the kids: Pulling away from family activities or physical presence, even when home, may indicate emotional overload.
Verbalizing feelings of failure or hopelessness: Expressions of feeling 'empty,' 'worthless,' or consumed by self-doubt are important cues.
If you notice these signs in a partner, start with a compassionate conversation. Let them know you see them—and that getting help isn't about being broken. It's about being supported. Meeting with a therapist or primary care provider can help dads access tools to manage their mental load.
'The association between paternal mental illness and poorer child development was robust,' researchers concluded, highlighting the importance of early intervention.
Related: The 'mental health walk' that wasn't: this mom's viral tiktok is our collective parenting nightmare
These trusted resources are a good place to start:
Postpartum Support International offers a dedicated helpline for dads.
The National Alliance on Mental Illness (NAMI) has support groups and local resources.
Pediatricians and family doctors can also provide referrals for mental health screenings and therapy.
When we support dads in the first two years, we're investing in the emotional well-being of the entire family. Because no parent should be expected to show up fully for their child while silently struggling.
The more we normalize emotional transparency and shared mental load, the stronger our families become.
Sources:
'Father's Mental Health in First Two Years May Influence Child Development, Study Finds.' June 2025. JAMA Pediatrics. Father's Mental Health in First Two Years May Influence Child Development, Study Finds.
'Men and Mental Health.' 2024. National Institute of Mental Health (NIMH). Men and Mental Health.
'Male depression: Understand the signs.' 2024. Mayo Clinic. Male depression: Understand the signs.
'Fathers and Families.' 2025. Fathers Mental Health Alliance. Fathers and Families.
'Help for Dads.' 2025. Postpartum Support International. Help for Dads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Exhale Wellness Recognized as the #1 Delta 9 THC Gummies by Onpattison
Exhale Wellness earns top spot for best Delta 9 gummies in 2025, recognized for quality, transparency, and customer satisfaction by Onpattison. Charlotte, NC, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onpattison has named Exhale Wellness the #1 Delta 9 gummy brand in its 2025 rankings, citing the company's emphasis on clean formulations, product transparency, and third-party testing. The annual list, compiled by the publication's wellness editorial team, highlighted 5 standout hemp-derived THC products that met high standards for safety, effectiveness, and consumer trust. Exhale Wellness's plant-based approach and commitment to rigorous quality control played a key role in securing the top spot for the brand. What Are Delta 9 Gummies? Delta 9 gummies are edible products containing Delta 9 tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. When sourced from federally legal hemp and formulated within compliant THC limits (less than 0.3% Delta 9 THC), these gummies offer a controlled, predictable way to consume THC. In its 2025 ranking, Onpattison recognized brands that deliver not only efficacy but also transparency and consumer safety in their Delta 9 offerings, criteria that Exhale Wellness met with distinction. Delta 9 THC Gummies: The Flagship Behind the #1 RankingAt the center of Onpattison's ranking is Exhale Wellness's Delta-9 Bottle Caps, the company's flagship gummy product. Editors cited the product's balanced potency, full-spectrum formulation, and transparency in testing as key reasons for awarding Exhale the top spot. Each bottle contains 450 mg of hemp-derived Delta 9 THC, formulated from full-spectrum hemp extract to preserve the natural cannabinoid and terpene profile. This approach contributes to what users often describe as a more rounded, longer-lasting experience compared to isolates. Bottle Caps were also recognized for their clean formulation, including vegan ingredients and naturally flavored profiles such as Cherry Cola, Lemon-Lime, and Orange. Exhale's use of U.S.-grown hemp and third-party lab testing ensures that each batch meets federal compliance standards outlined in the 2018 Farm Bill. In this context, Exhale's published Certificates of Analysis (COAs), available to consumers, were noted as a strong indicator of transparency and consumer trust. Additional Features That Contributed to the Best Ranking In naming Exhale Wellness the #1 Delta 9 thc gummy brand of 2025, Onpattison highlighted several distinguishing factors beyond formulation alone. One was consistency in potency, with each gummy delivering a reliable 15 mg of hemp-derived Delta 9 THC, an important element for responsible dosing and user experience. The product's clean, vegan formulation was also a factor in the ranking. Made with plant-based pectin, natural flavors, and free from artificial additives, Bottle Caps reflects growing consumer demand for health-conscious, non-GMO edibles. While the Bottle Caps line is relatively new, Onpattison noted Exhale's overall brand reputation for quality and transparency. Across its product offerings, Exhale has earned strong consumer reviews for consistency, ease of use, and customer service, qualities that helped set the brand apart in a competitive evaluation process. Why Exhale Wellness Was Chosen as Delta 9 Gummies? Exhale Wellness earned the top spot in Onpattison's 2025 Delta 9 thc gummy rankings due to its commitment to product integrity, transparency, and user trust. The evaluation highlighted several standout factors that contributed to the brand's placement: Transparent Sourcing and Lab TestingEach batch of Exhale's Delta 9 gummies is verified through third-party lab testing, with publicly available Certificates of Analysis (COAs) confirming cannabinoid content, potency, and product safety. This level of transparency was a key differentiator in the ranking process. Clean, Plant-Based FormulationsThe editorial team emphasized Exhale's use of organic, non-GMO ingredients and vegan-friendly formulations made without artificial additives. The use of pectin over gelatin reflects a thoughtful approach to ingredient sourcing. Established Brand ReputationWhile Bottle Caps is one of the newer products in Exhale's portfolio, the brand's track record of quality and responsiveness was cited as a contributing factor. Consistent consumer satisfaction across Exhale's broader product line reinforced its credibility. Balanced Potency and Full-Spectrum EffectThe magazine also acknowledged the company's use of full-spectrum hemp extract, which preserves a range of cannabinoids and terpenes for a more comprehensive user experience. This format, paired with clearly labeled dosing, supports a wide range of consumer preferences. Editorial Criteria That Set Exhale Wellness Apart In evaluating the best Delta 9 THC gummies for its 2025 ranking, Onpattison applied a broad set of criteria reflecting the current standards for product quality and consumer trust. Exhale Wellness met or exceeded expectations across the following key areas: Sourcing and Agricultural Standards Exhale uses hemp grown in the United States under regulated agricultural practices, minimizing exposure to pesticides, heavy metals, or synthetic additives. Domestic sourcing was a baseline requirement in the magazine's review process. Potency and Dose TransparencyEach gummy contains a clearly labeled 15 mg of Delta 9 THC. The publication highlighted brands that offer reliable, consistent dosing, a crucial element for consumers managing intake responsibly. Clean Ingredient Profile Formulations were evaluated for ingredient transparency. Exhale's plant-based, vegan gummies, made without artificial colorants or high-fructose corn syrup, were noted for addressing evolving consumer preferences. Third-Party Lab Testing and COA Access Brands without published lab results were excluded from consideration. Exhale's publicly accessible Certificates of Analysis (COAs) confirmed potency, cannabinoid breakdown, and absence of contaminants. Flavor and Product Consistency Taste and texture factored into the overall experience. Exhale's use of natural flavoring and consistent formulation across batches contributed positively to its assessment. Responsiveness Exhale's reputation for customer support, shipping reliability, and product consistency helped distinguish it in a crowded market. Editorial staff considered both consumer sentiment and company transparency during the review. Legal Compliance All selected brands were required to meet the 2018 Farm Bill threshold of 0.3% Delta 9 THC by dry weight. Exhale's compliance was verified through both internal documentation and third-party reports. Exhale Wellness's Delta 9 Gummies Availability Exhale Wellness's Delta 9 gummies, including the award-winning Bottle Caps line, are available for purchase through the company's official website. Each product listing includes detailed lab reports (COAs), ingredient information, and dosage specifications to support consumer transparency. All Exhale Wellness Delta 9 THC products comply with the 2018 Farm Bill, containing no more than 0.3% THC by dry weight. Products are available for shipment to states where hemp-derived Delta 9 THC is permitted, and all customers must be 21 years or older to purchase. Shipping practices adhere to federal and state-level compliance requirements. FAQs about Delta THC Gummies What is Delta 9 THC? Delta 9 tetrahydrocannabinol (THC) is the primary psychoactive compound found in cannabis. It interacts with the body's endocannabinoid system and is known for producing effects such as euphoria and relaxation. When derived from hemp and used within legal limits, it can be formulated into federally compliant wellness products. Are Exhale Wellness's Delta 9 Gummies Legal? Yes. Exhale Wellness's Delta 9 gummies are made from hemp-derived THC and contain no more than 0.3% Delta 9 THC by dry weight, in accordance with the 2018 Farm Bill. Federal legality does not guarantee state-level approval, so consumers are advised to check local laws before purchasing. What makes Exhale Wellness different from other Delta 9 gummy brands? Exhale Wellness was recognized by Onpattison for its product consistency, lab-tested transparency, and clean ingredient profile. The brand uses non-GMO, vegan-friendly formulations and publishes third-party Certificates of Analysis for every batch. How strong are the best Delta 9 Gummies from Exhale Wellness? Each gummy contains 15 mg of hemp-derived Delta 9 THC. This dosage format offers a balanced and consistent experience and is intended to support responsible use among both new and experienced consumers. Do Exhale Wellness's gummies ship nationwide? Exhale Wellness ships to U.S. states where hemp-derived Delta 9 THC products are legally permitted. While the products are federally legal, shipping availability is subject to state-specific regulations. How long do the effects last? The effects of hemp-derived Delta 9 gummies typically last between 6 and 9 hours, depending on individual factors such as body chemistry, metabolism, and tolerance. Onset time may be delayed due to digestion. How should Delta 9 THC be dosed? Dosing recommendations vary by user. For those new to Delta 9 THC, a lower dose (such as 2.5 to 5 mg) is generally suggested to gauge individual response. Gradual adjustment over time can help maintain a safe and comfortable experience. Conclusion Exhale Wellness's selection as the top Delta 9 gummy brand in Onpattison's 2025 rankings reflects the company's emphasis on ingredient transparency, consistent dosing, and third-party lab testing. The recognition highlights Exhale's approach to federally compliant hemp products at a time when consumer standards for quality and accountability in the wellness space are rising. For more information, visit CONTACT: Company Name: Exhale Wellness Phone Number: (323) 448-3810 Email: support@ Official Address: Charlotte, NC 28273, United StatesSign in to access your portfolio
Medscape
7 minutes ago
- Medscape
Cannabis Use Disorder Tied to Benign Salivary Tumors
TOPLINE: Cannabis use disorder (CUD) was associated with a greater than fivefold increased risk for benign tumors of major salivary glands compared to not having CUD, a new retrospective study showed. Additionally, the elevated risk persisted beyond 5 years of follow-up and particularly affected the parotid salivary gland. METHODOLOGY: As previous research showed a link between cigarette smoking and benign gland tumors, the current investigators wanted to assess whether CUD was also associated with these tumors. In this retrospective cohort study, they analyzed electronic medical records from 66 US-based healthcare organizations. Incidence of any benign major salivary gland tumor and parotid salivary gland tumor was compared between nearly 184,000 adults with a history of hospital outpatient visit and CUD and more than 6 million individuals without CUD between 2005 and 2025. Propensity score matching was applied to adjust for clinical characteristics, including age, race, ethnicity, tobacco use, nicotine use disorder, and a history of radiation. TAKEAWAY: The incidence of benign tumor of any major salivary gland and that of the parotid salivary gland was higher in the CUD group than in the non-CUD group (0.08 vs 0.02% and 0.05 vs 0.01%, respectively). Relative risk for any benign major salivary gland tumor was higher in the CUD vs non-CUD group at all timepoints between index event and outcome assessment (risk ratio [RR] for any time, 5.2; RR for 0-5 years, 4.3; RR for ≥ 5 years, 5.0). Relative risk for benign tumor of the parotid salivary gland was also increased after a diagnosis of CUD (RR for any time, 5.2; RR for 0-5 years, 4.9; RR for ≥ 5 years, 3.9). IN PRACTICE: 'The elevated relative risk of benign parotid tumors and the persistent association over time highlight potential site-specific outcomes of cannabis use,' the investigators wrote. 'Future prospective research with large samples and data on cannabis doing, method of use, and benign salivary gland neoplasm pathology is required to further assess and confirm this association,' they added. SOURCE: The study was led by Tyler J. Gallagher, MD, Keck School of Medicine, University of Southern California, Los Angeles. It was published online on July 17 in JAMA Otolaryngology-Head & Neck Surgery. LIMITATIONS: The study was constrained by the absence of cannabis dosage information and histologic data on benign salivary gland tumors and a limited long-term follow-up. DISCLOSURES: The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
37 minutes ago
- Medscape
HF Drug Combo Improves Outcomes but Sparks Safety Concerns
TOPLINE: In patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), adding the mineralocorticoid receptor antagonist (MRA) spironolactone to the SGLT2 inhibitor, dapagliflozin significantly lowered the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) compared with dapagliflozin alone, but led to hyperkalemia and a greater decline in the estimated glomerular filtration rate (eGFR). METHODOLOGY: Researchers conducted a prospective crossover trial to evaluate the efficacy and safety of combination therapy with dapagliflozin and spironolactone vs dapagliflozin alone in patients with HFmrEF/HFpEF. They included 108 adults (median age, 76 years; 57% women) with symptomatic heart failure (New York Heart Association class II-IV), a left ventricular ejection fraction > 40%, and elevated levels of NT-proBNP (median, 746 pg/mL); all had an eGFR of 30 mL/min/1.73 m 2 or more and a serum potassium level of 5.5 mmol/L or lower. or more and a serum potassium level of 5.5 mmol/L or lower. Patients were randomly assigned to 12-week treatment sequences of either 10 mg/d dapagliflozin alone or a combination of dapagliflozin and spironolactone, with spironolactone dosed from 25 mg every other day up to 25 mg daily. The primary outcome was the difference in circulating levels of log-transformed NT-proBNP between treatment with the dapagliflozin-spironolactone combination and dapagliflozin alone. Secondary outcomes included the difference in the proportion of patients achieving a reduction of 20% or more in levels of NT-proBNP and effects on parameters such as eGFR, serum potassium levels, and blood pressure. TAKEAWAY: The combination of dapagliflozin and spironolactone reduced log NT-proBNP by 0.11 units compared with dapagliflozin alone (P = .035), corresponding to an 11% relative reduction. The odds of achieving a reduction in levels of NT-proBNP of 20% or more were 2.27-fold greater with the combination therapy than with dapagliflozin alone (P = .016). While the combination therapy reduced systolic blood pressure by 5.2 mm Hg (P = .002) compared with dapagliflozin alone, eGFR reduced by 6.4 mL/min/1.73 m 2 (P < .001) and serum potassium increased by 0.32 mmol/L (P < .001). (P < .001) and serum potassium increased by 0.32 mmol/L (P < .001). Hyperkalemia and declines in kidney function were both more frequent and more pronounced with the combination therapy than with dapagliflozin alone. IN PRACTICE: 'SOGALDI-PEF is the first dedicated randomized trial to evaluate the impact of dapagliflozin/spironolactone combination on clinically important biomarkers and key safety parameters,' the researchers reported. 'In patients with HFmrEF/HFpEF, dapagliflozin/spironolactone combination led to a greater NT-proBNP reduction than dapagliflozin or spironolactone alone. A greater eGFR decline and serum potassium increase with dapagliflozin/spironolactone combination was observed,' they added. Acute declines in kidney function after the initiation of treatment with an SGLT2 inhibitor or MRA remains 'a major reason for premature drug discontinuation,' experts wrote in an editorial accompanying the journal article. 'A well-intentioned strategy of simultaneous initiation of SGLT2i and MRAs may paradoxically increase the likelihood of premature discontinuation, undermining the benefits of combination therapy,' they added. SOURCE: This study was led by João Pedro Ferreira, MD, PhD, of the Universidade do Porto in Portugal. It was published online on July 28, 2025, in the Journal of the American College of Cardiology. LIMITATIONS: As a relatively small trial, this study was not adequately powered to evaluate hard clinical outcomes, including hospitalizations or mortality. The administration of treatments in an open-label fashion may have influenced the decisions of physicians and patients. Different operators performed and analyzed the echocardiograms. DISCLOSURES: This study received support from AstraZeneca-Produtos Farmacéuticos, Lda, and national funds through FCT — Portuguese Foundation for Science and Technology. Several authors reported receiving research support and consulting or speaker fees from multiple pharmaceutical and healthcare companies, including AstraZeneca. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
